Comparison Between Rebamipide 2% Versus Autologous Serum
Status:
Completed
Trial end date:
2018-07-09
Target enrollment:
Participant gender:
Summary
Two-period, controlled, randomized and open clinical trial. The sample was composed of adult
women with moderate to severe hypo secretory dry eye associated with Sjögren's syndrome, who
attended the ocular surface office, derived from the general ophthalmology clinic, from the
Rheumatology or Immunology department. The three interventions were randomized: autologous
serum (GSA), Rebamipida 2% (GR) and a combined treatment (GSAR). The following were used as
outcome measures: OSDI self-administered questionnaire (Ocular Surface Disease Index),
tear-rupture time (BUT), fluorescein staining, Bengal Rose staining and Schirmer's test
without anesthesia to assess the answer to each treatment